期刊
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021
卷 72, 期 -, 页码 399-413出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-070119-120448
关键词
colorectal cancer; circulating tumor DNA; ctDNA; cell-free DNA; cfDNA; minimal residual disease; treatment response monitoring; EGFR rechallenge
Patient-specific biomarkers are crucial for precision medicine, and in the case of colorectal cancer (CRC), analyzing cfDNA can be used for detecting minimal residual disease, monitoring treatment response, identifying drivers of treatment sensitivity and resistance, and guiding therapeutic strategies. As diagnostic technology continues to improve, more innovative applications of cfDNA analysis are expected.
Patient-specific biomarkers form the foundation of precision medicine strategies. To realize the promise of precision medicine in patients with colorectal cancer (CRC), access to cost-effective, convenient, and safe assays is critical. Improvements in diagnostic technology have enabled ultrasensitive and specific assays to identify cell-free DNA (cfDNA) from a routine blood draw. Clinicians are already employing these minimally invasive assays to identify drivers of therapeutic resistance and measure genomic heterogeneity, particularly when tumor tissue is difficult to access or serial sampling is necessary. As cfDNA diagnostic technology continues to improve, more innovative applications are anticipated. In this review, we focus on four clinical applications for cfDNA analysis in the management of CRC: detecting minimal residual disease, monitoring treatment response in the metastatic setting, identifying drivers of treatment sensitivity and resistance, and guiding therapeutic strategies to overcome resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据